Edgewise Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$2,252
Gross Profit
-534
-525
1,719
EBITDA
-37,627
-34,280
-33,379
EBIT
-38,161
-34,805
-33,912
Net Income
-31,497
-28,525
-30,143
Net Change In Cash
0
0
2,252
Free Cash Flow
-26,320
-28,895
-26,991
Cash
43,485
30,264
86,097
Basic Shares
93,515
87,567
64,774

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$0
$0
$0
$0
Gross Profit
-1,732
-538
-272
-185
EBITDA
-112,806
-21,541
-42,943
-17,007
EBIT
-114,357
-22,079
-43,215
-17,192
Net Income
-100,163
-15,397
-42,139
-17,054
Net Change In Cash
0
0
0
0
Cost of Revenue
6,427
-89,350
Free Cash Flow
-97,693
-58,181
-34,175
-14,837
Cash
86,097
351,947
280,789
104,916
Basic Shares
63,723
53,593
49,500
49,217

Earnings Calls

Quarter EPS
2024-09-30
-$0.36
2024-06-30
-$0.34
2024-03-31
-$0.33
2023-12-31
-$0.47